Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.

EJHaem · 2022 · PMC9175947 · PMID 35846031

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

20.0%) and showed a trend toward longer median PFS (3.2 months vs. 2.8 months) and mDOR (NR [95% CI, 4.7–NE] vs. 1.9 months [95% CI, 1.0–NE]) compared with patients with classifier‐negative disease (Table S5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.